{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:21:00Z","timestamp":1793366460211,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40265-020-01277-0","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T01:04:05Z","timestamp":1583370245000},"page":"495-500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Osilodrostat: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sean","family":"Duggan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"1277_CR1","unstructured":"European Medicines Agency. Osilodrostat (Isturisa\u00ae): summary of product characteristics. 2020. https:\/\/ec.europa.eu\/. Accessed 20 Jan 2020."},{"issue":"5","key":"1277_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40261-017-0497-0","volume":"37","author":"S Armani","year":"2017","unstructured":"Armani S, Ting L, Sauter N, et al. Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig. 2017;37(5):465\u201372.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1277_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","volume":"19","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing\u2019s disease. Pituitary. 2016;19(2):138\u201348.","journal-title":"Pituitary"},{"key":"1277_CR4","unstructured":"Recordati, Novartis P. Recordati: acquisition of worldwide rights to Signifor\u00ae and osilodrostat (LCI699) completed [media release]. 23 Oct 2019. http:\/\/www.recordati.com."},{"key":"1277_CR5","unstructured":"Recordati. Recordati to acquire worldwide rights to Signifor\u00ae and osilodrostat (LCI699) [media release]. 12 Jul 2019. http:\/\/www.recordati.com."},{"key":"1277_CR6","unstructured":"Recordati. RECORDATI: Isturisa\u00ae (osilodrostat) approved [media release]. 15 Jan 2020. https:\/\/www.recordati.com\/."},{"key":"1277_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12967-014-0340-9","volume":"12","author":"J Menard","year":"2014","unstructured":"Menard J, Rigel DF, Watson C, et al. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects. J Transl Med. 2014;12:340.","journal-title":"J Transl Med"},{"issue":"8","key":"1277_CR8","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1210\/jc.2019-00217","volume":"104","author":"SG Creemers","year":"2019","unstructured":"Creemers SG, Feelders RA, de Jong FH, et al. Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing Syndrome: an in vitro study. J Clin Endocrinol Metab. 2019;104(8):3437\u201349.","journal-title":"J Clin Endocrinol Metab"},{"key":"1277_CR9","doi-asserted-by":"crossref","unstructured":"Han K, Tauchmanova L, Atkinson S, et al. Pharmacokinetics of Osilodrostat following single and multiple doses of osilodrostat in healthy subjects and patients with Cushing\u2019s disease [abstract]. In: 21st European Congress of Endocrinology. 2019.","DOI":"10.1530\/endoabs.63.GP162"},{"key":"1277_CR10","doi-asserted-by":"crossref","unstructured":"Breitschaft A, Tauchmanova L, Han K, et al. Osilodrostat has no clinically relevant effect on the pharmacokinetic (PK) profile of a monophasic oral contraceptive in healthy females receiving cortisol replacement therapy [abstract no. SAT-443]. J Endocr Soc. 2019;3(Suppl 1).","DOI":"10.1210\/js.2019-SAT-443"},{"key":"1277_CR11","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.63.OC3.1","author":"R Pivonello","year":"2019","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, et al. Osilodrostat provides clinical benefit over 48\u00a0weeks in patients with Cushing disease: results from the LINC 3 study. Endocr Abstr. 2019. https:\/\/doi.org\/10.1530\/endoabs.63.OC3.1.","journal-title":"Endocr Abstr"},{"key":"1277_CR12","doi-asserted-by":"crossref","unstructured":"Biller BMK, Newell-Price J, Fleseriu M, et al. Osilodrostat treatment in Cushing\u2019s Disease (CD): results from a phase III, multicenter, double-blind, randomized withdrawal study (LINC 3) [abstract no. OR16-2]. J Endocr Soc. 2019;3(Suppl 1).","DOI":"10.1210\/js.2019-OR16-2"},{"issue":"4","key":"1277_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1210\/jc.2013-2117","volume":"99","author":"X Bertagna","year":"2014","unstructured":"Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s Disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014;99(4):1375\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"1277_CR14","unstructured":"Pivonello R, Hatipoglu B, Molitch ME, et al. Osilodrostat can provide control of urinary free Cortisol for over 2.5\u00a0years in patients with Cushing\u2019s disease: Results from an extension to the linc-2 study [abstract no. OR22]. Endocr Rev. 2017;38(3 Suppl 1)."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01277-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01277-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01277-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T19:49:18Z","timestamp":1614887358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01277-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01277-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"5 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sean Duggan is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}